Peter G. Linde

Corporate Officer/Principal bei Walden Biosciences, Inc.

57 Jahre

Health Technology

Finance

Health Services

Aktive Positionen von Peter G. Linde

Unternehmen	Position	Beginn	Ende
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Corporate Officer/Principal	11.10.2022	-

Unternehmen	Position	Beginn	Ende
MORPHIC HOLDING, INC.	Technik-/Wissenschafts-/F&E-Leiter	17.03.2020	31.12.2021
FIBROGEN, INC.	Corporate Officer/Principal	-	-
ACCELERON PHARMA INC.	Corporate Officer/Principal	-	-

Massachusetts Institute of Technology

Undergraduate Degree

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
MORPHIC HOLDING, INC.	Health Technology
FIBROGEN, INC.	Health Technology

Private Unternehmen	2
Acceleron Pharma, Inc. Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.	Health Technology
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Health Services

Private Unternehmen

Health Technology

Health Services